Lv6
2969 积分 2023-07-21 加入
Molecular Evidence of Multiorgan Damage in Patients with Immune-Related Adverse Events
11小时前
待确认
Is PORTEC-4a the tipping point in endometrial cancer management?
18小时前
待确认
Hyperbaric oxygen therapy for chronic radiotherapy‐related adverse effects: A clinically focused review
1天前
待确认
Neoadjuvant radio-chemo-immunotherapy impact on postoperative patient-reported outcomes in oesophageal cancer
1天前
待确认
The Aging Microenvironment is a Determinant of Immune Exclusion and Metastatic Fate in Pancreatic Cancer
1天前
待确认
Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
4天前
已完结
Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2)
4天前
已完结
Preoperative chemoradiotherapy plus pembrolizumab for esophageal squamous cell carcinoma (ACTS-29)
4天前
已完结
Real-World Guide for Delivering Immunotherapy With Radiation Therapy
4天前
已完结
A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity
7天前
已完结
皖公网安备34019202002308
